Gilead Sciences (GILD) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
76.98% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
318.57% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-14.16% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-21.46% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
6.98% |
| 10 |
Novartis Ag |
109.78 Bn |
109.09 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
26.25% |
| Dec 31, 2025 |
10.21% |
| Sep 30, 2025 |
19.61% |
| Jun 30, 2025 |
19.68% |
| Mar 31, 2025 |
273.25% |
| Dec 31, 2024 |
67.90% |
| Sep 30, 2024 |
-21.28% |
| Jun 30, 2024 |
2.16% |
| Mar 31, 2024 |
-64.33% |
| Dec 31, 2023 |
-2.79% |
| Sep 30, 2023 |
81.36% |
| Jun 30, 2023 |
32.23% |
| Mar 31, 2023 |
-13.12% |
| Dec 31, 2022 |
-15.04% |
| Sep 30, 2022 |
52.46% |
| Jun 30, 2022 |
-14.77% |
| Mar 31, 2022 |
-76.49% |
| Dec 31, 2021 |
11.77% |
| Sep 30, 2021 |
8.61% |
| Jun 30, 2021 |
-4.52% |
